Identification of new prognostic biomarkers for Stage III metastatic melanoma patients

Accurately predicting disease outcome among patients bearing Stage III metastatic melanoma is complex. However, current advances in personalized medicine call for ever more precise prognostic assessments, as these have a significant impact not only on the design and analysis of clinical trials, but...

Descripción completa

Detalles Bibliográficos
Autores principales: Kakavand, Hojabr, Scolyer, Richard A, Thompson, John F, Mann, Graham J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3820811/
https://www.ncbi.nlm.nih.gov/pubmed/24228228
http://dx.doi.org/10.4161/onci.25564
_version_ 1782290208375439360
author Kakavand, Hojabr
Scolyer, Richard A
Thompson, John F
Mann, Graham J
author_facet Kakavand, Hojabr
Scolyer, Richard A
Thompson, John F
Mann, Graham J
author_sort Kakavand, Hojabr
collection PubMed
description Accurately predicting disease outcome among patients bearing Stage III metastatic melanoma is complex. However, current advances in personalized medicine call for ever more precise prognostic assessments, as these have a significant impact not only on the design and analysis of clinical trials, but also on therapeutic decision-making.
format Online
Article
Text
id pubmed-3820811
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-38208112013-11-13 Identification of new prognostic biomarkers for Stage III metastatic melanoma patients Kakavand, Hojabr Scolyer, Richard A Thompson, John F Mann, Graham J Oncoimmunology Author's View Accurately predicting disease outcome among patients bearing Stage III metastatic melanoma is complex. However, current advances in personalized medicine call for ever more precise prognostic assessments, as these have a significant impact not only on the design and analysis of clinical trials, but also on therapeutic decision-making. Landes Bioscience 2013-09-01 2013-07-03 /pmc/articles/PMC3820811/ /pubmed/24228228 http://dx.doi.org/10.4161/onci.25564 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Kakavand, Hojabr
Scolyer, Richard A
Thompson, John F
Mann, Graham J
Identification of new prognostic biomarkers for Stage III metastatic melanoma patients
title Identification of new prognostic biomarkers for Stage III metastatic melanoma patients
title_full Identification of new prognostic biomarkers for Stage III metastatic melanoma patients
title_fullStr Identification of new prognostic biomarkers for Stage III metastatic melanoma patients
title_full_unstemmed Identification of new prognostic biomarkers for Stage III metastatic melanoma patients
title_short Identification of new prognostic biomarkers for Stage III metastatic melanoma patients
title_sort identification of new prognostic biomarkers for stage iii metastatic melanoma patients
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3820811/
https://www.ncbi.nlm.nih.gov/pubmed/24228228
http://dx.doi.org/10.4161/onci.25564
work_keys_str_mv AT kakavandhojabr identificationofnewprognosticbiomarkersforstageiiimetastaticmelanomapatients
AT scolyerricharda identificationofnewprognosticbiomarkersforstageiiimetastaticmelanomapatients
AT thompsonjohnf identificationofnewprognosticbiomarkersforstageiiimetastaticmelanomapatients
AT manngrahamj identificationofnewprognosticbiomarkersforstageiiimetastaticmelanomapatients

Ejemplares similares